“…The comparison revealed overrepresentation of more than 80 transcription factors at hypomethylated enhancer sites, including master regulators that determine cell fate during stem, myeloid and lymphoid cell differentiation such as FLI1, GFI1B, and PU.1 (Figure S5B). Many of the transcription factors identified have also been implicated in hematopoietic diseases, including FLI1, LMO2, and RUNX1 in T-ALL (Cleveland et al, 2014; Mok et al, 2014; Smeets et al, 2013; Smith et al, 2014), and PU.1 and RUNX1 in AML (Cancer Genome Atlas Research, 2013; Gerloff et al, 2015). These findings suggest that Dnmt3a loss results in the demethylation of previously methylated, functionally relevant enhancers during leukemogenesis, potentially increasing accessibility of these regions to transcription factors.…”